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Abstract
With the growing use of genome-wide screens for cis-regulatory elements, there is a pressing
need for platforms that enable fast and cost-effective experimental validation of identified hits in
relevant developmental and tissue contexts. Here, we describe a murine embryonic stem cell
(ESC) based system that facilitates rapid analysis of putative transcriptional enhancers.
Candidate enhancers are targeted with high efficiency to a defined genomic locus via
recombinase-mediated cassette exchange (RMCE). Targeted ESCs are subsequently
differentiated in vitro into desired cell types, where enhancer activity is monitored by reporter
gene expression. As a proof of principle, we analyzed a previously characterized, Sonic
hedgehog (Shh)-dependent, V3 interneuron progenitor (pV3)-specific enhancer for the Nkx2.2
gene, and observed highly specific enhancer activity. Given the broad potential of ESCs to
generate a spectrum of cell types, this system can serve as an effective platform for the
characterization of gene regulatory networks controlling cell fate specification and cell function.3
Enhancers are cis-regulatory DNA elements that modulate transcription independent of their
position and orientation with respect to the transcriptional start site (Banerji et al., 1981). A
given enhancer contains binding sites for different transcription factors; the specific combination
of DNA-protein interactions determines whether the enhancer is active or silent, ensuring
appropriate spatial and temporal activity of target genes. As key regulators of gene expression,
enhancers play critical roles in development, disease, and evolution (Ben-Tabou de-Leon and
Davidson, 2007; Visel et al., 2009b). Consequently, a systematic comprehensive decoding of
their regulatory actions is an important goal, and especially so for the understanding of how cell
fates are determined on differentiation of stem cells.
The advent of powerful genomic technologies has allowed for the unprecedented
genome-wide prediction of enhancer elements (Rada-Iglesias et al., 2011; Visel et al., 2009a).
However, to rapidly validate and characterize the vast number of genomic regions with
regulatory potential remains a considerable challenge, particularly in mammals. In a typical
enhancer assay, a putative enhancer element is placed upstream of a minimal promoter driving a
reporter gene whose expression is analyzed in an appropriate experimental system (Loots, 2008).
There are significant drawbacks associated with many of the existing methodologies. For
example, transient transfections of reporter constructs are easy to perform but assess the elements
in multiple copies and in a non-chromosomal context. At the other end of the spectrum, mouse
transgenesis offers a more natural in vivo context, yet it is expensive, time-consuming, and
laborious. This is further aggravated by the fact that the copy number and integration sites of
reporter constructs cannot be controlled, thus necessitating the analysis of multiple lines per
element to control for position effects at the site of integration and copy number differences that4
confound analysis. Given these and other constraints, it is critical to develop faster, scalable, and
more cost-effective experimental systems that replicate normal regulatory mechanisms.
Embryonic stem cells (ESCs) are well suited for this purpose, since they are amenable to
controlled genetic manipulations (Capecchi, 1989; Turan et al., 2011) and can be differentiated
into a variety of cell lineages closely replicating the normal programs of cell fate specification
(Keller, 2005). The general utility of ESC based approaches for analysis of cis-regulatory
elements has been shown (Xian et al., 2005; Zhang et al., 2008). However, a high-throughput
application requires the development of an efficient, reproducible and rapid strategy that enables
position-independent activity of potentially any enhancer of interest. To these ends, we
developed a novel system that enables reproducible targeting of candidate enhancers through
recombinase-mediated cassette exchange (RMCE) at the Gt(ROSA)26Sor locus (hereafter
referred to as the Rosa26 locus) (Turan et al., 2011; Zambrowicz et al., 1997). The Rosa26 locus
is a transcriptionally permissive environment and eliminates potential position effects associated
with random integration (Zambrowicz et al., 1997). Targeted ESCs can be assayed directly or
differentiated into various cell types to assess tissue-specific enhancer activity. As a proof of
principle, we generated neuralized embryoid bodies (EBs) from ESCs and analyzed Sonic
hedgehog (Shh)-mediated activation of the Nkx2.2 gene in V3 interneuron progenitors (pV3)
(Briscoe et al., 1999). We selected a pV3-specific enhancer of Nkx2.2 that has previously been
characterized in transgenic mice and shown to be dependent upon a single Gli transcription
factor binding site (Lei et al., 2006; Vokes et al., 2007). Characterization of this enhancer in
vitro recapitulates the in vivo analysis, validating our enhancer analysis platform. In addition, we
demonstrate how the system can be further optimized to improve its capability for high-
throughput applications.5
To allow for high-throughput analysis of putative enhancers, we took advantage of the
high efficiency of RMCE and selected the Rosa26 locus as a target site, as its activity in most
cell types indicates a chromatin configuration that is predicted to permit normal, position-
independent regulation of test enhancers (Zambrowicz et al., 1997). To facilitate RMCE, we
targeted a FLPo recombinase expression cassette, flanked by F3 and FRT recognition sites, to the
Rosa26 locus (cell line Rosa26 (FLPo)) (Fig. 1a). This configuration allows for high
recombination efficiency, prevents internal recombination, and provides an endogenous source
of recombinase activity that is conveniently self-terminated upon recombination (Raymond and
Soriano, 2007; Seibler and Bode, 1997; Seibler et al., 2005). To prevent random integration and
achieve stringent selection of correctly targeted clones, we used a neomycin resistance gene
(Neo) that lacks a promoter and an ATG translation start codon (Fig. 1b). Only upon successful
recombination, a splice acceptor and ATG codon engineered in the Rosa26 (FLPo) line allow for
Neo expression from the endogenous Rosa26 promoter (Beard et al., 2006). Indeed, we observed
98% selection efficiency (48/49 recombinant colonies), in line with similar targeting strategies
(Seibler et al., 2005; Wang et al., 2007) (Fig. 1c and data not shown). A correctly integrated
enhancer-reporter cassette was flanked by single copies of the full-length chicken β-globin
insulator to block local influences on enhancer activity (Burgess-Beusse et al., 2002; Chung et
al., 1997). Together, all these features enable a highly efficient analysis, where the need to screen
dozens of colonies for correct integration and assess multiple clones per construct due to position
effects is eliminated.
Once we optimized the parameters for consistent targeting results, we explored a number
of protocol modifications to improve the scalability of the approach (Table 1). On average, at
least one recombinant colony per million electroporated cells was obtained consistently under all6
conditions tested. As a result, we have adapted our system to a 6-well-plate format, allowing for
moderate-throughput applications. Additional optimization, such as testing the use of even fewer
cells per electroporation or lipofection-based delivery methods, may improve on targeting
efficiency with regard to the number of input cells.
Next, we validated our platform for enhancer analysis (schematized in Fig. 2). A 420-bp
enhancer located 1.7 kb upstream of the Nkx2.2 coding sequence recapitulates the pV3-specific
Nkx2.2 expression pattern in vivo (Lei et al., 2006). This activity is Shh-dependent; mutation of a
unique Gli factor binding site – Gli proteins are the transcriptional effectors of the Shh pathway –
abolishes enhancer activity. Rosa26 (FLPo) cells were targeted with this element and subjected
to a 5-day EB differentiation protocol that utilizes the neuralizing activity of retinoic acid (RA),
in conjunction with a small-molecule agonist of the Shh pathway (SAG), to generate a mix of
Shh-dependent neural progenitors that includes Nkx2.2
+, pV3 cells (Chen et al., 2002; Wichterle
et al., 2002). As expected, nearly all Nkx2.2
+ cells co-expressed the β-gal reporter (91.1 ± 1.7%)
(Fig. 3i-l, q; data from two independent clones). We did detect a population of β-gal single-
positive cells (20.6 ± 3.0% of all β-gal
+ cells), consistent with in vivo observations (Lei et al.,
2006). This likely reflects the absence of sequences that refine Nkx2.2 expression after Shh
activation, notably those that suppress activity in the floor plate. Importantly, enhancer activity
was Shh-dependent. First, omission of the Shh agonist abolished reporter along with Nkx2.2
expression (2.4 ± 1.1% β-gal
+ cells) (Fig. 3e-h, r). Further, a mutation of the critical Gli binding
site similarly abrogated reporter expression (1.8 ± 0.6% β-gal
+ cells) (Fig. 3m-p, q, r). An
enhancer-less reporter showed minimal levels of reporter activation (1.6 ± 0.4% β-gal
+ cells)
despite appropriate derivation of V3 progenitors (25.9 ± 4.2% Nkx2.2
+ cells), indicating that
promoter background is negligible and does not influence the analysis (Fig. 3a-d, q, r).7
Collectively, these data demonstrate that transcriptional activity of the enhancer element can be
reliably analyzed in this in vitro system.
We also developed an exchange vector with a nuclear lacZ::GFP fusion reporter to
simplify scoring of nuclear signals. Using this modified construct, we obtained essentially
identical results (91.2 ± 1.5% Nkx2.2
+ cells co-expressed reporter for the wild-type enhancer;
15.5 ± 2.3% reporter cells were single-positive) (Supp. Fig. 1). Besides facilitating scoring of
immunostained samples, this reporter also enables potential FACS analysis with the GFP marker
as an additional means of quantitatively assessing enhancer activity.
In conclusion, we have developed a novel murine ESC based system for fast, scalable,
and cost-effective analysis of putative transcriptional enhancers. Our methodology can be
applied to other neural and non-neural enhancers, given the broad array of cell types that can be
generated from ESCs (Keller, 2005), and potentially to human ESCs, since protocols for their
genetic manipulation and directed differentiation are available (Hockemeyer and Jaenisch, 2010;
Irion et al., 2008). The same general strategy can also be implemented for the analysis of other
types of cis-regulatory elements, such as silencers or insulators. Thus, our system provides a
versatile tool that could find broad application in large-scale studies of the transcriptional gene
regulation in ESCs or diverse developmental and tissue contexts.
Methods
Plasmid construction
To construct the Rosa26 targeting vector (pRosa-17), a PGK-Neo-3xpA cassette was replaced
with ATG-F3-PGK-Puro-pA and PGK-FLPo-pA cassettes in the pBigT vector (Srinivas et al.,8
2001). The former fragment was PCR amplified from the pPGKpuro vector (Tucker et al., 1996)
(ATG and F3 sequences were included in the primer tails), and the latter obtained by excision
from the pPGKFLPobpA vector (Raymond and Soriano, 2007). Next, an FRT-1xIns fragment
was PCR amplified from the pHSP68lacZ2XINS vector (Vokes et al., 2007) (FRT sequence was
included in the primer tail), inserted downstream of FLPo-pA to replace a pA sequence in the
pBigT backbone, and the entire ATG-to-1xIns fragment cloned into pRosaPAS (Mao et al.,
2005).
To construct the exchange vector (pXCHG3), an F3-ΔATGNeo-pA-3xpA cassette was
PCR amplified from pBigT (Srinivas et al., 2001) (ATG was excluded and F3 sequence included
in the primer tails), and an FRT site generated by annealing of pre-synthesized oligonucleotides
(IDT). The two fragments were ligated and inserted downstream of a pA sequence cloned from
pPGKFLPobpA (Raymond and Soriano, 2007) in pBlueScript (Stratagene). A 1xIns-hsp68-lacZ-
pA cassette (Vokes et al., 2007) was cloned immediately upstream of the FRT site. F3 and FRT
sequences used in all vectors were respectively: GAAGTTCCTATTCCGAAGTTCCTATTCTT-
CAAATAGTATAGGAACTTC and GAAGTTCCTATACTTTCTAGAGAATAGGAACTTCG-
GAATAGGAACTTC. Nkx2.2 enhancer variants were subsequently inserted at a unique KpnI
site upstream of the hsp68 promoter. The Nkx2.2-420bp and Nkx2.2-GliM constructs were
generated as previously described (Lei et al., 2006).
To generate the modified exchange vector (pXCHG-IHZG), 1xIns and hsp68 sequences
were PCR amplified from pHSP68lacZ2XINS (Vokes et al., 2007), and cloned into the
pBlueScript-KS(+) vector (Stratagene) to generate pBS-Ins-Hsp68. Next, the lacZ coding
sequence was PCR amplified from pHSP68lacZ2XINS (Vokes et al., 2007), and a 3X-NLS-
GFP-pA fragment PCR amplified from pCIG (Megason and McMahon, 2002). The two9
fragments were cloned into pBS-Ins-Hsp68 to generate pBS-1xIns-hsp68-lacZ-3XNLS-GFP-pA
(pIHZG). An attR1-attR2 Gateway
® selection cassette (Invitrogen) was inserted immediately
upstream of hsp68, and the entire 1xIns-to-pA fragment used to replace 1xIns-hsp68-lacZ-pA in
pXCHG3. The Nkx2.2-420bp enhancer was cloned into the pENTR1A vector (Invitrogen) and
inserted in pXCHG-IHZG via Gateway
® LR recombination, as per manufacturer’s protocol
(Invitrogen).
For the optimization experiments, a pCAGGS-FLPo expression vector was constructed
by cloning the FLPo coding sequence (Raymond and Soriano, 2007) downstream of the CAGGS
promoter of pCIG (Megason and McMahon, 2002).
Gene targeting
For generation of the Rosa26 (FLPo) line, 20 μg targeting vector was linearized with SwaI,
phenol/chloroform purified, and added to 10
7 V6.5 cells (Eggan et al., 2001) in 800 μl cold PBS.
Cells were electroporated at 230 V and 500 μF using Gene Pulser (BioRad), and plated onto 10-
cm dishes with puromycin-resistant MEFs. 3 μg/μl puromycin (Sigma) was added on the
following day, medium was changed daily, and colonies were picked after 6 days of selection, as
described previously (Hogan et al., 1994). Picked clones were expanded in 96-well plates with
MEF feeders. Properly targeted clones were identified by junction PCR, expanded, and stocked.
Primer sequences for genotyping were as follows: for 5’ end, CCGCCTAAAGAAGAGGCTGT-
GCTTTGG (Rosa05) and CAAGGAAACCCTGGACTACTGCGCCC (Rosa15); for 3’ end,
CTGGGCTGCTGGTTGATGACCCTGC (Rosa02) and GGGCAATCTGGGAAGGTTCCTTA-
AGAA (Rosa11).10
For RMCE, 20 μg circular exchange vector was added to 6 x 10
6 Rosa26 (FLPo) cells in
800 μl cold PBS. Cells were electroporated at 240 V and 500 μF using Gene Pulser (BioRad),
and plated onto 10-cm dishes with neomycin-resistant MEFs. For 6-well-plate format, the same
conditions were used, except that 4 x 10
6 cells were electroporated and 1.5 x 10
6 cells plated per
well in 6-well plates. 300 μg/ml G418 (Geneticin
®; Invitrogen) was added on the following day
and medium was changed daily. Colonies were picked 6 days after the onset of selection,
expanded in 48-well plates with MEF feeders, and cultured in complete medium containing 200
μg/ml G418. Appropriate recombination events were identified by junction PCR, targeted cells
were expanded, and frozen stocks prepared. Primer sequences for genotyping were as follows:
for 5’end, CTCTGAGTTGTTATCAGTAAGGGAGC (Xchg01) and GATTGTCTGTTGTGC-
CCAGTCATAG (Xchg11); for 3’ end, GTCGCTACCATTACCAGTTGGTCT (Xchg02) and
CCCAGATGACTCCTATCCTCCATTT (Xchg12). PCR conditions were as follows: 94ºC for 2
min; 35 cycles of 94ºC for 10 s, 55ºC for 30 s, 68ºC for 1 min (5’ end) or 2 min (3’ end); 68ºC
for 5 min. The Taq PCR Core Kit was used following manufacturer’s protocol (Qiagen).
For testing different targeting conditions, a given parameter was modified and the effect
of the modification on the yield of recombinant colonies determined as indicated in Table 1.
When exogenous FLPo was provided, this was achieved by co-electroporation with 20 µg
pCAGGS-FLPo. Each condition was repeated in at least three replicates and data on colony yield
are presented as mean ± SEM, with the exceptions noted in Table 1.
ESC culture and directed differentiation
All ESC lines were maintained using standard procedures, in complete ESC medium containing
15% fetal bovine serum (FBS; Hyclone) and 1,000 units/ml recombinant leukemia inhibitory11
factor (LIF; Chemicon) (Hogan et al., 1994). Directed differentiation followed published
procedures (Wichterle et al., 2002). Two days after EB formation, medium was replaced and
supplemented with 500 nM retinoic acid (RA; Sigma) and, where applicable, 1 μM of the Shh-
agonist, SAG (Alexis Biochemicals). EBs were cultured for additional 3 days to induce neural
progenitor stages, at which point they were harvested, fixed, sectioned and processed for
immunostaining, as described previously (Wichterle et al., 2002).
Immunocytochemistry and quantification
Primary antibodies were as follows: rabbit anti-β-galactosidase (1:40,000, Cappel), and mouse
anti-Nkx2.2 (1:20, Developmental Studies Hybridoma Bank). Secondary antibodies were
appropriately-conjugated IgG (H+L) Alexa Fluor
® 488 or 568 (1: 500, Invitrogen). Stained
sections were imaged on a LSM510/710 META confocal microscope (Zeiss). To quantify co-
expression, β-gal and Nkx2.2 immunoreactivity was quantified by individual cell counts, and the
overlap determined relative to the number of Nkx2.2
+ cells. To calculate the proportion of β-gal
single-positive cells, the latter were counted and represented as a percentage of all β-gal
+ cells.
To calculate the total proportion of β-gal
+ or Nkx2.2
+ cells, the respective cells were counted and
represented as a percentage of Hoechst-positive cells. In all cases, regions corresponding to
fields of view (40X magnification) of at least five different EBs (three for total counts and no-
SAG controls) were scored for each sample. Data are presented as mean ± SEM. Differences
between samples were compared by one-way ANOVA, where statistical significance is defined
as P < 0.05.12
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Figure Legends
Figure 1. Engineering the Rosa26 locus for RMCE analysis of enhancer activity. (a)
Schematic of the strategy to generate the Rosa26 (FLPo) allele. ‘X’ marks the insertion point
within the Rosa26 locus (genome coordinates chr6:113,026,031 (mm9)). (b) Schematic of the
RMCE used to target putative enhancers. Gray arrowheads denote primers used for PCR
screening for positive clones. (c) Representative PCR results from a targeting experiment. The
highlighted bands indicate correct integration at the 5’ (left) and 3’ (right) ends. 1-7, individual
clones; NC, negative control (Rosa (FLPo) DNA).
Abbreviations: SA, splice acceptor; ATG, translation initiation codon; F3/FRT, recombination
sites; PGK, phosphoglycerokinase promoter; Puro, puromycin resistance gene; pA,
polyadenylation/transcription stop signal; FLPo, codon-optimized FLP recombinase; Ins, chicken
β-globin insulator; ΔATG-Neo, promoter/ATG-less neomycin resistance gene; Enh, putative
enhancer; hsp68, heat shock protein 68 minimal promoter; lacZ, E. coli β-galactosidase gene.17
Figure 2. Flowchart of the experimental analysis of enhancer activity in neuralized EBs.
Putative enhancers (enh) are coupled to the hsp68 minimal promoter driving the expression of a
nuclear lacZ::GFP reporter (lacZnGFP), and introduced at a defined locus (Rosa26) in ESCs via
RMCE. Following highly efficient selection for neomycin resistance, successful recombinants
are expanded and differentiated in vitro to desired cell types, which results in the expression of
specific markers (red and orange). Neuralized EB sections are immunostained and analyzed
quantitatively to determine overlap between the expression of the reporter gene (green) and an
endogenous gene of interest (red). For abbreviations, see Fig. 1. *This time is given for the
differentiation protocol used in this study.
Figure 3. Shh-pathway-dependent activation of an Nkx2.2 enhancer in ESC-derived neural
progenitors. (a-d) Neural progenitors harboring an empty exchange vector. Activity of the
Nkx2.2 enhancer (Nkx2.2-420bp) in the absence (e-h), or presence of SAG (i-l); arrowheads in
inset (k) point to Nkx2.2
+β-gal
+ cells. (m-p) SAG-treated neural progenitors harboring an Nkx2.2
enhancer with a mutated Gli binding site (Nkx2.2-GliM). Magnification: 40X. (q) Quantification
of β-gal/Nkx2.2 co-expression. **, P < 0.01. (r) Quantification of Nkx2.2 (purple) and β-gal
(blue) expression.18192021
Tables
Table 1. Summary of tested protocol modifications.
Protocol modification Number of recombinant colonies
(per 10
6 electroporated cells)
Number of
electroporated cells
(x10
6)
4.0 1.0
* ± 0.1
4.8 1.4
* ± 0.3
6.4 2.9 ± 0.1
Amount of
electroporated DNA
(μg/10
6 cells)
4.2 2.5
8.3 1.7
12.5 2.9
Exogenous FLPo No 2.1
* ± 0.5
Yes 2.8
* ± 0.7
Seeding cell density
(x10
5/cm
2)
0.3 1.4
* ± 0.3
0.6 1.6
* ± 0.1
1.5 2.9
* ± 1.7
5.0 1.2
* ± 0.2
*Average of at least three replicates.22
Supplementary Figure Legend
Supplementary Figure 1. Nkx2.2-enhancer-driven expression of a nuclear reporter. Activity
of the wild-type Nkx2.2 enhancer (Nkx2.2-420bp) in the absence (a-d) or presence (e-h) of SAG;
arrowheads in inset (g) point to Nkx2.2
+β-gal
+ cells. Magnification: 40X.23